Further analysis of the ARTISTIC trial

The Lancet Oncology

Volumn 10, Issue 9, 2009, Pages 841-842

  Sasieni, Peter ^a   Castle, Philip E ^b   Cuzick, Jack ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER INCIDENCE; CANCER PREVENTION; CANCER SCREENING; COLPOSCOPY; HUMAN; LETTER; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS;

CERVICAL INTRAEPITHELIAL NEOPLASIA; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 69149095476     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70246-3     Document Type: Letter

References (4)

1. Cuzick J., Arbyn M., Sankaranarayanan R., Tsu V., et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26 suppl 10 (2008) K29-K41
2. Dillner J., Rebolj M., Birembaut P., et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 337 (2008) a1754
3. Sherman M.E., Lorincz A.T., Scott D.R., et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 95 (2003) 46-52
4. Cuzick J., Clavel C., Petry K.U., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119 (2006) 1095-1101